Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Rosiglitazone Discontinuation May Interfere With Medication Use and Glycaemic Control: Presented at EASD By Jill Stein ROME -- September 8, 2008 -- Many patients who discontinued their rosiglitazone as a result of recent reports that the oral antidiabetic might increase the risk of ischaemic cardiovascular events were not switched to another oral antidiabetic drug and developed poor glucose control, researchers reported here at the European Association for the Study of Diabetes (EASD) 2008. Peter Weissman, MD, University of Miami School of Medicine, Miami, Florida, and colleagues evaluated the effect of rosiglitazone discontinuation on glycaemic control in type 2 diabetics. Their study, presented on September 8, represents an interim analysis of data from a large database that contains about 7.9 million patient records of treatment by 2,600 US-based doctors. The researchers identified 5,933 patients with type 2 diabetes with 2 or more prescriptions for rosiglitazone monotherapy or combination therapy in a 12-month period prior to May 21, 2007, who received no new prescriptions for rosiglitazone in the subsequent 90-day period. Of these patients, 11% had receiving the drug as monotherapy and 89% as part of combination therapy. After discontinuation, 45% were switched to another oral antidiabetic drug as monotherapy, 33% received combination oral antidiabetic therapy, 9% received insulin alone, and nearly 13% had no evidence of being switched to any oral antidiabetic drug or insulin. Patients who had previously been on rosiglitazone monotherapy experienced an increase in fasting plasma glucose (FPG) levels from 132.5 to 140.4 mg/dL after discontinuation of the drug, with 53% of patients at goal before stopping rosiglitazone versus 49% afterwards. Likewise, patients who had been on combination rosiglitazone therapy developed a significant increase in FPG levels after discontinuation (134.5 to 143.7 mg/dL, P = .025). This group had a decrease in the number of patients at their target FPG from 43% before to 39.8% after discontinuation. Dr. Weissman noted that a possible shortcoming of the trial is that the length of follow-up was short. Also, the number of monotherapy patients with lab values pre- and post-May 21 was small. "These preliminary analyses suggest concern for patients who stopped rosiglitazone after May 21, 2007, particularly those on combination therapy, who had a decrease in glycaemic control," Dr. Weissman and colleagues wrote in their poster presentation. "Evidence has demonstrated that a loss of glycaemic control is associated with an increased risk of long-term complications." Funding for the study was provided by GSK. [Presentation title: Impact of Rosiglitazone Discontinuation on Glycemic Control. Abstract 918] E-mail this page to a friend or colleague! To print, use this version